Lipoprotein(a) and Cardiovascular Risk: New Insights.
作者信息
Varzideh Fahimeh, Kansakar Urna, Santulli Gaetano
机构信息
Albert Einstein College of Medicine, New York City, NY.
University of Naples "Federico II", Italy.
出版信息
Eur J Prev Cardiol. 2024 Nov 15. doi: 10.1093/eurjpc/zwae378.
Abstract
摘要
相似文献
1
Lipoprotein(a) and Cardiovascular Risk: New Insights.脂蛋白(a)与心血管风险：新见解
Eur J Prev Cardiol. 2024 Nov 15. doi: 10.1093/eurjpc/zwae378.
2
[Design and rationale: Observational Study of the Argentine Group for the Study of Lipoprotein (a)].[设计与原理：阿根廷脂蛋白（a）研究小组的观察性研究]
Hipertens Riesgo Vasc. 2025 Jan-Mar;42(1):13-17. doi: 10.1016/j.hipert.2024.07.005. Epub 2024 Oct 8.
3
Sex Differences in the Association Between Lipoprotein(a) and Cardiovascular Outcomes: The MGB Lp(a) Registry.脂蛋白(a)与心血管结局关联中的性别差异：MGB Lp(a)注册研究
J Am Heart Assoc. 2025 May 6;14(9):e035353. doi: 10.1161/JAHA.124.035353. Epub 2025 Apr 16.
4
The Effects of Colchicine on Lipoprotein(a) and Oxidized Phospholipid Associated Cardiovascular Disease Risk.秋水仙碱对脂蛋白（a）及氧化磷脂相关心血管疾病风险的影响。
Eur J Prev Cardiol. 2024 Oct 30. doi: 10.1093/eurjpc/zwae355.
5
Elevated lipoprotein(a) levels linked to new-onset atrial fibrillation: insights from a retrospective cohort study.脂蛋白(a)水平升高与新发心房颤动相关：一项回顾性队列研究的见解
Eur J Prev Cardiol. 2025 Jul 14;32(9):769-777. doi: 10.1093/eurjpc/zwaf063.
6
Impact of diabetes on risk of major adverse cardiovascular events associated with lipoprotein(a) levels in patients with established atherosclerotic cardiovascular disease.糖尿病对已确诊动脉粥样硬化性心血管疾病患者中与脂蛋白(a)水平相关的主要不良心血管事件风险的影响。
Eur J Prev Cardiol. 2025 Mar 11. doi: 10.1093/eurjpc/zwaf036.
7
Association between lipoprotein(a) concentration and outcomes after percutaneous coronary intervention: A systematic review and meta-analysis.脂蛋白(a)浓度与经皮冠状动脉介入治疗后结局的关联：一项系统评价和荟萃分析。
Arch Cardiovasc Dis. 2025 Jun 24. doi: 10.1016/j.acvd.2025.05.009.
8
Global Variation in Lipoprotein(a) Levels Among Patients With Coronary Heart Disease: Insights From the INTERASPIRE Study and Implications for Emerging Lp(a)-Lowering Therapies.冠心病患者脂蛋白(a)水平的全球差异：INTERASPIRE研究的见解及对新兴降脂蛋白(a)疗法的启示
J Am Coll Cardiol. 2025 Jun 3;85(21):2028-2042. doi: 10.1016/j.jacc.2025.04.010.
9
Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial.在START（抗逆转录病毒治疗的战略时机）试验中，HIV阳性参与者立即与延迟启动抗逆转录病毒治疗时心血管疾病风险因素的变化。
J Am Heart Assoc. 2017 May 22;6(5):e004987. doi: 10.1161/JAHA.116.004987.
10
Relationship between lipoprotein(a) levels, cardiovascular outcomes and death in patients with chronic kidney disease: a systematic review of prospective studies.脂蛋白(a)水平与慢性肾脏病患者心血管结局和死亡的关系：前瞻性研究的系统评价。
J Nephrol. 2023 Jul;36(6):1549-1559. doi: 10.1007/s40620-023-01590-3. Epub 2023 Apr 8.
引用本文的文献
1
The nonlinear association between lipoprotein(a) and major adverse cardiovascular events in acute coronary syndrome patients with three-vessel disease.急性冠状动脉综合征三支血管病变患者中脂蛋白(a)与主要不良心血管事件之间的非线性关联。
Sci Rep. 2025 Jan 11;15(1):1720. doi: 10.1038/s41598-025-86154-0.
本文引用的文献
1
Intra-individual Variability in Lipoprotein(a) Levels: Findings from a Large Academic Health System Population.脂蛋白(a)水平的个体内变异性：来自大型学术医疗系统人群的研究结果。
Eur J Prev Cardiol. 2024 Oct 24. doi: 10.1093/eurjpc/zwae341.
2
The mysterious lipoprotein(a): moving towards further understanding of its atherogenic role.神秘的脂蛋白(a)：迈向对其致动脉粥样硬化作用的进一步理解
Eur J Prev Cardiol. 2025 Jan 27;32(2):128-130. doi: 10.1093/eurjpc/zwae321.
3
Association between lipoprotein(a), LPA genetic risk score, aortic valve disease, and subsequent major adverse cardiovascular events.脂蛋白(a)、LPA 遗传风险评分与主动脉瓣疾病及随后主要不良心血管事件的相关性。
Eur J Prev Cardiol. 2024 Aug 9;31(10):1303-1311. doi: 10.1093/eurjpc/zwae100.
4
Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES.在ODYSSEY OUTCOMES研究中，阿利西尤单抗对脂蛋白(a)质量和摩尔浓度变化的影响及其与后续心血管事件风险的比较。
Eur J Prev Cardiol. 2024 Aug 9;31(10):e75-e78. doi: 10.1093/eurjpc/zwae110.
5
Impact of elevated lipoprotein(a) on coronary artery disease phenotype and severity.脂蛋白(a)升高对冠状动脉疾病表型和严重程度的影响。
Eur J Prev Cardiol. 2024 May 11;31(7):856-865. doi: 10.1093/eurjpc/zwae007.
6
Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research.脂蛋白(a)与心血管疾病：筛选证据以指导未来的研究。
Eur J Prev Cardiol. 2024 May 11;31(7):903-914. doi: 10.1093/eurjpc/zwae032.
7
Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis.他汀类药物治疗与脂蛋白(a)水平：一项系统评价和荟萃分析。
Eur J Prev Cardiol. 2022 May 5;29(5):779-792. doi: 10.1093/eurjpc/zwab171.
8
Finding very high lipoprotein(a): the need for routine assessment.发现极高水平的脂蛋白(a)：常规评估的必要性。
Eur J Prev Cardiol. 2022 May 5;29(5):769-776. doi: 10.1093/eurjpc/zwab167.
9
Plasma lipoprotein(a) measured in the routine clinical care is associated to atherosclerotic cardiovascular disease during a 14-year follow-up.在 14 年的随访中，常规临床护理中测量的血浆脂蛋白(a)与动脉粥样硬化性心血管疾病有关。
Eur J Prev Cardiol. 2022 Feb 9;28(18):2038-2047. doi: 10.1093/eurjpc/zwab016.
10
Relationship between lipoprotein(a) concentrations and intima-media thickness: a healthy population study.脂蛋白(a)浓度与内中膜厚度的关系：一项健康人群研究。
Eur J Prev Cardiol. 2012 Dec;19(6):1290-5. doi: 10.1177/1741826711423216. Epub 2011 Sep 13.
Zotero 插件